Sio Gene Therapies Inc. Common Stock
SIOX
SIOX was delisted on the 22nd of March, 2023.
42 hedge funds and large institutions have $28.4M invested in Sio Gene Therapies Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 10 increasing their positions, 11 reducing their positions, and 14 closing their positions.
92% more capital invested
Capital invested by funds: $14.8M → $28.4M (+$13.6M)
9% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 11
13% less funds holding
Funds holding: 48 → 42 (-6)
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
29% less call options, than puts
Call options by funds: $249K | Put options by funds: $353K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$13.2M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$9.14M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$3.69M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$2.73M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$2.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWNA
Marshall Wace North America
New York
|
-$452K |
| 2 |
Axa
Paris,
France
|
-$262K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$242K |
| 4 |
Primecap Management
Pasadena,
California
|
-$168K |
| 5 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
-$146K |
SIOX Hedge Fund Activity: Q1 2020 in Review
42 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q1 2020, worth a combined $28.4M — up 92% from $14.8M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of SIOX and 10 opened new positions — a net loss of 4 holders — while 11 trimmed existing stakes and 10 added.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $13.2M. The largest seller was Marshall Wace North America, exiting entirely with an estimated $452K sold.
- 42 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q1 2020, down from 48 in Q4 2019.
- Funds reported $28.4M of Sio Gene Therapies Inc. Common Stock stock for Q1 2020, up 92% quarter-over-quarter.
- 10 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q1 2020 and 14 closed out, a net change of -4 holders.
- The largest Sio Gene Therapies Inc. Common Stock buyer in Q1 2020 was Consonance Capital Management, an estimated $13.2M added.
- The largest Sio Gene Therapies Inc. Common Stock seller in Q1 2020 was Marshall Wace North America, an estimated $452K sold.
Based on aggregated 13F filings for Q1 2020.